Transcription factor E2F DNA-binding domain inhibitor peptides and their use

US6841385B2 · kind B2 · utility

Assignee

• TopoTarget UK Limited · GB

Inventors

• Rolf Muller · Marburg, DE
• Roland Kontermann · Jeffery Road, DE
• Silvia Montigiani · Siena, IT

Key dates

• Filing date: Jul 26, 2001
• Grant date: Jan 11, 2005
• Expiry date: Sep 14, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides peptides which bind to the DNA binding domain of transcription factor E2F, and inhibit cell cycle progression. Peptides include FWLRFT (SEQ ID NO:1); WVRWHF (SEQ ID NO:2); WHFIFW (SEQ ID NO:3); IWLSGLSRGVWVSFP (SEQ ID NO:4); and GSRILTFRSGSWYAS (SEQ ID NO:5) and derivatives based upon these sequences. Compositions and the use of the peptides in inhibiting cell cycle progression, such as in uncontrolled cell proliferation, are also provided.